Results 1 to 10 of about 10,096 (214)

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. [PDF]

CA Cancer J Clin
Abstract Although poly(adenosine diphosphate‐ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first‐line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA‐mutated/homologous recombination‐deficient (HRD) patients, is lacking.
Wu L, Wang J, Li Q, Wang D, Zhang C, Tang J, Zhang G, Hao M, Yao D, Gao Q, Zhang Y, An R, Yin R, Wang L, Xia B, Zhou Q, Yang H, Zhu J, Jiang K, Chen Z, Wu Q, Duan W, Huang Y, Zhang H, Wei S, Li G, Meng Y, Wang K, Yang X, Huang X, Pan L, Yu J, Lou G, Zhang Y, Zhou H, Guo X, Yang H, Cheng X, Li X, Wang W, Zhao H, Li Y, Yang Y, Lin A, Cheng W, Chen L, Xie X, Di W, Hu Y, Chen M, Wen H, Cai L, Wu X, Lin Z, Wang Q, Yang X, Li N.   +56 more
europepmc   +2 more sources

Ovarios poliquísticos y síndrome de ovario poliquísticos

RECIMUNDO, 2022
El síndrome de ovarios poliquisticos es una patología que puede comprometer el ciclo reproductivo de la mujer, y de no ser diagnosticado y tratado oportunamente puede generar complicaciones que pueden llegar a hasta 2.7 veces de desarrollar cáncer endometrial o metabólicas y cardiovasculares.
Luz Angélica Salazar Carranza, Verónica Alexandra Ayala Esparza, Stalin Fabián Martínez Mora, Janeth Aurora Cruz Villegas   +3 more
openaire   +1 more source

Cáncer de ovario

Medicine - Programa de Formación Médica Continuada Acreditado, 2021
Resumen El cancer de ovario es la segunda neoplasia ginecologica mas comun y la que produce mayor mortalidad. El carcinoma seroso de alto grado es el subtipo histologico mas frecuente. Su presentacion clinica suele ser insidiosa, de modo que la mayoria de las veces el diagnostico se realiza con la enfermedad avanzada intraabdominal. La estadificacion
M. Pérez Martelo, V. Cebey López, M. Mateos González, J.F. Cueva Bañuelos   +3 more
openaire   +3 more sources

Immunotherapies in ovarian cancer

EJC Supplements, 2020
Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet ...
Elena García-Martínez, J. Alejandro Pérez-Fidalgo   +1 more
doaj   +1 more source

Patient involvement in research within the Gynecological Cancer InterGroup: A call to action for a systematic approach: Results from a survey

Health Science Reports, Volume 6, Issue 12, December 2023., 2023
Abstract Background and Aims Involving patients in research, not only as trial subjects, is not a newly established practice. Over the last two decades, patient roles have gradually expanded to become active research contributors, creating a more patient‐centered research landscape.
Ivana Nohová, John Andrews, Bénédicte Votan, Austin Miller, Jalid Sehouli, Regina Berger   +5 more
wiley   +1 more source

Causes of pregnancy arrest in the canine species

Reproduction in Domestic Animals, Volume 58, Issue S2, Page 72-83, September 2023., 2023
Abstract In the canine species, early pregnancy arrest before 30–40 days of pregnancy will induce intra‐uterine embryonic or foetal resorption, with very few clinical signs. If no genital examination by ultrasound is performed at that time, it will often remain unnoticed and the bitch will be qualified as infertile. It is only when pregnancy stops at a
Alain Fontbonne
wiley   +1 more source

Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer

Journal of Global Oncology, 2019
PURPOSE: Little is known about the genetic predisposition to breast and ovarian cancer among the Chilean population, in particular genetic predisposition beyond BRCA1 and BRCA2 mutations.
Christina Adaniel, Francisca Salinas, Juan Manuel Donaire, Maria Eugenia Bravo, Octavio Peralta, Hernando Paredes, Nuvia Aliaga, Antonio Sola, Paulina Neira, Carolina Behnke, Tulio Rodriguez, Soledad Torres, Francisco Lopez, Claudia Hurtado   +13 more
doaj   +1 more source

Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial

Cancer, Volume 129, Issue 12, Page 1846-1855, 15 June 2023., 2023
Abstract Background The PRIMA/ENGOT‐OV26/GOG‐3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first‐line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
Mansoor R. Mirza, Antonio González‐Martín, Whitney S. Graybill, David M. O’Malley, Lydia Gaba, Oi Wah Stephanie Yap, Eva M. Guerra, Peter G. Rose, Jean‐François Baurain, Sharad A. Ghamande, Hannelore Denys, Emily Prendergast, Carmela Pisano, Philippe Follana, Klaus Baumann, Paula M. Calvert, Jacob Korach, Yong Li, Izabela A. Malinowska, Divya Gupta, Bradley J. Monk   +20 more
wiley   +1 more source

Top advances of the year: Cervical cancer

Cancer, Volume 129, Issue 5, Page 657-663, 1 March 2023., 2023
Abstract Cervical cancer continues to affect women in the United States and throughout the world despite an effective vaccine against human papillomavirus and cancer screening programs. For the women who develop cervical cancer, surgery, radiation, and chemotherapy have been the mainstays of treatment for years.
Sarah E. Podwika, Linda R. Duska
wiley   +1 more source

Ovario Poliquístico

Revista Peruana de Ginecología y Obstetricia, 2015
Ovario Poliquístico - Fisiopatología, Cuadro Clínico, Diagnóstico, Tratamiento.
José Peñaloza J., Mario Comparato, Oscar Ponce de León Bardales, Adolfo Rechkemmer   +3 more
openaire   +1 more source